dc.contributor.author
Fransecky, L.
dc.contributor.author
Neumann, M.
dc.contributor.author
Heesch, S.
dc.contributor.author
Schlee, C.
dc.contributor.author
Ortiz-Tanchez, J.
dc.contributor.author
Heller, S.
dc.contributor.author
Mossner, M.
dc.contributor.author
Schwartz, S.
dc.contributor.author
Mochmann, L. H.
dc.contributor.author
Isaakidis, K.
dc.contributor.author
Bastian, L.
dc.contributor.author
Kees, U. R.
dc.contributor.author
Herold, T.
dc.contributor.author
Spiekermann, K.
dc.contributor.author
Goekbuget, N.
dc.contributor.author
Baldus, C. D.
dc.date.accessioned
2018-06-08T03:32:59Z
dc.date.available
2016-10-19T10:02:06.964Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15413
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-19601
dc.description.abstract
Background GATA3 is pivotal for the development of T lymphocytes. While its
effects in later stages of T cell differentiation are well recognized, the
role of GATA3 in the generation of early T cell precursors (ETP) has only
recently been explored. As aberrant GATA3 mRNA expression has been linked to
cancerogenesis, we investigated the role of GATA3 in early T cell precursor
acute lymphoblastic leukemia (ETP-ALL). Methods We analyzed GATA3 mRNA
expression by RT-PCR (n = 182) in adult patients with T-ALL. Of these, we
identified 70 of 182 patients with ETP-ALL by immunophenotyping. DNA
methylation was assessed genome wide (Illumina Infinium® HumanMethylation450
BeadChip platform) in 12 patients and GATA3-specifically by pyrosequencing in
70 patients with ETP-ALL. The mutational landscape of ETP-ALL with respect to
GATA3 expression was investigated in 18 patients and validated by Sanger
sequencing in 65 patients with ETP-ALL. Gene expression profiles (Affymetrix
Human genome U133 Plus 2.0) of an independent cohort of adult T-ALL (n = 83)
were used to identify ETP-ALL and investigate GATA3low and GATA3high
expressing T-ALL patients. In addition, the ETP-ALL cell line PER-117 was
investigated for cytotoxicity, apoptosis, GATA3 mRNA expression, DNA
methylation, and global gene expression before and after treatment with
decitabine. Results In our cohort of 70 ETP-ALL patients, 33 % (23/70) lacked
GATA3 expression and were thus defined as GATA3low. DNA methylation analysis
revealed a high degree of GATA3 CpG island methylation in GATA3low compared
with GATA3high ETP-ALL patients (mean 46 vs. 21 %, p < 0.0001). Genome-wide
expression profiling of GATA3low ETP-ALL exhibited enrichment of
myeloid/lymphoid progenitor (MLP) and granulocyte/monocyte progenitor (GMP)
genes, while T cell-specific signatures were downregulated compared to
GATA3high ETP-ALL. Among others, FLT3 expression was upregulated and
mutational analyses demonstrated a high rate (79 %) of FLT3 mutations.
Hypomethylating agents induced reversal of GATA3 silencing, and gene
expression profiling revealed downregulation of hematopoietic stem cell genes
and upregulation of T cell differentiation. Conclusions We propose GATA3low
ETP-ALL as a novel stem cell-like leukemia with implications for the use of
myeloid-derived therapies.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Journal of Hematology & Oncology. - 9 (2016), Artikel Nr. 95
dcterms.bibliographicCitation.doi
10.1186/s13045-016-0324-8
dcterms.bibliographicCitation.url
http://jhoonline.biomedcentral.com/articles/10.1186/s13045-016-0324-8
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000025578
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000007238
dcterms.accessRights.openaire
open access